8-K current report · filed May 5, 2026

Orthofix Medical Inc. (OFIX) 8-K Current Report: May 5, 2026

Item 2.02Item 7.01Item EX-99.1OFIX overview

Short answer

Orthofix Medical Inc. (OFIX) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Filing provides non-GAAP framework, not fiscal 2026 results or period-specific financial figures.

Orthofix Medical Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Filing provides non-GAAP framework, not fiscal 2026 results or period-specific financial figures
  • Adjusted EBITDA is management’s primary operating metric for evaluating business performance and resource allocation
  • Exclusions include SeaSpine merger costs, litigation, M6 restructuring, acquisitions, share compensation, and acquired-asset amortization
  • Investors should reconcile adjusted measures to GAAP because exclusions may represent recurring economic costs or affect cash flows
  • Long-term normalized effective tax rate assumption set at 28% for 2025 and 2026 adjusted results

Item 7.01 · Regulation FD Disclosure

  • Investor-relations presentation designated for use throughout fiscal 2026
  • Exhibit 99.2 may be modified for presentations to investors and analysts
  • Reg FD filing signals potential dissemination of presentation materials to market participants

Item EX-99.1 · Exhibit EX-99.1

  • Q1 net sales $196.7M, up 1.6% reported; pro forma constant-currency sales up 2.7% excluding discontinued M6 discs
  • Spine growth 6% and Therapeutic Solutions growth 5%, while Limb Reconstruction delivered 10.2% reported growth
  • Net loss improved to $(20.9)M from $(53.1)M, but pro forma adjusted EBITDA declined to $9.7M from $11.4M
  • Cash increased to $120.9M after $63.97M financing inflows; free cash flow remained negative at $(28.3)M
  • Full-year guidance reaffirmed: sales $850M–$860M, adjusted EBITDA $95M–$98M, and positive free cash flow excluding legal settlements

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Orthofix Medical Inc. 8-K filings

Get the next OFIX 8-K as it lands

Follow OFIX for push alerts, or ask the research agent what this filing means.